Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.
[congenital adrenal hyperplasia]
Increased
morbidity
and
mortality
associated
with
conventional
glucocorticoid
replacement
therapy
for
primary
adrenal
insufficiency
(
primary
AI
;
estimated
prevalence
93
-
140
/
million
)
,
secondary
AI
(
estimated
prevalence
,
150
-
280
/
million
,
respectively
)
or
congenital
adrenal
hyperplasia
(
estimated
prevalence
,
approximately
65
/
million
)
may
be
due
to
the
inability
of
typical
glucocorticoid
treatment
regimens
to
reproduce
the
normal
circadian
profile
of
plasma
cortisol
.
A
once-daily
modified-release
formulation
of
hydrocortisone
has
been
developed
to
provide
a
plasma
cortisol
profile
that
better
mimics
the
daytime
endogenous
profile
of
cortisol
.
Here
,
we
describe
the
protocol
for
the
European
Adrenal
Insufficiency
Registry
(
EU
-AIR
)
,
an
observational
study
to
assess
the
long
-term
safety
of
modified-release
hydrocortisone
compared
with
conventional
glucocorticoid
replacement
therapies
in
routine
clinical
practice
(
ClinicalTrials
.
gov
identifier
:
NCT
01661387
)
.
Patients
enrolled
in
EU
-AIR
have
primary
or
secondary
AI
and
are
receiving
either
modified-release
or
conventional
glucocorticoid
replacement
therapy
.
The
primary
endpoints
of
EU
-AIR
are
the
incidence
of
intercurrent
illness
,
adrenal
crisis
and
serious
adverse
events
(
SAEs
)
,
as
well
as
the
duration
of
SAEs
and
dose
changes
related
to
SAEs
.
Data
relating
to
morbidity
,
mortality
,
adverse
drug
reactions
,
dosing
and
concomitant
therapies
will
be
collected
.
Patient
diaries
will
record
illness-related
dose
changes
between
visits
.
All
decisions
concerning
medical
care
are
made
by
the
registry
physician
and
patient
.
Enrolment
is
targeted
at
achieving
3600
patient-
years
of
treatment
(
1800
patient-
years
per
group
)
for
the
primary
analysis
,
which
is
focused
on
determining
the
non-inferiority
of
once-daily
modified-release
replacement
therapy
compared
with
conventional
glucocorticoid
therapy
.
Recruitment
began
in
August
2012
and
,
as
of
March
2014
,
801
patients
have
been
enrolled
.
Fifteen
centres
are
participating
in
Germany
,
the
UK
and
Sweden
,
with
recruitment
soon
to
be
initiated
in
the
Netherlands
.
EU
-AIR
will
provide
a
unique
opportunity
not
only
to
collect
long
-term
safety
data
on
a
modified-release
preparation
of
glucocorticoid
but
also
to
evaluate
baseline
data
on
conventional
glucocorticoid
replacement
.
Such
data
should
help
to
improve
the
treatment
of
AI
.
Diseases
Validation
Diseases presenting
"conventional glucocorticoid replacement therapy for primary adrenal insufficiency"
symptom
congenital adrenal hyperplasia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom